STOCKHOLM, Sept. 4, 2023 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a pioneering developer of augmented intelligence-based solutions for skin disorders, is thrilled to introduce Dan Walker as the new VP of US Commercial Operations.
Dan brings with him a wealth of experience, having previously served as the Senior Director of Commercial Insights, Market Access, and Field Reimbursement at Biofrontera Inc., a renowned player in the Dermatology market specializing in actinic keratosis treatment through PDT (Photodynamic Therapy). His leadership played a pivotal role in successfully launching Biofrontera Inc. in the US market, securing FDA approval for their innovative drug and device combination product in Dermatology.
With over 24 years of extensive experience in the US healthcare landscape, Dan has held various leadership positions spanning Sales, Training, Commercial Operations, Commercial Insights, Key Accounts, Market Access, and Field Reimbursement. His proven track record in building high-performing teams within the US Dermatology sector and his profound understanding of the complex US medical benefit reimbursement environment make him an invaluable asset in driving SciBase’s sales and market access efforts in the United States.
“We view Dan’s expertise and determination as instrumental to SciBase’s success in the US, especially as we continue to expand and consolidate our recent accomplishments in reimbursement with two Medicare Administrative Contractors (MACs). We’ve recently expanded our team in both Texas and California to further our growth in reimbursement and sales. We warmly welcome Dan to the SciBase family and eagerly anticipate the accelerated growth of our US market presence,” said Tord Lendau, Chairman of the Board at SciBase.
About SciBase and Nevisense
Step into the world of cutting-edge medical technology, where SciBase reigns supreme from its Stockholm, Sweden headquarters. We are the pioneers of a revolutionary point-of-care platform that’s transforming the way we detect skin cancer and a host of other skin conditions, all without invasive procedures.
At SciBase, we’re on a mission to blend the brilliance of artificial intelligence with the power of Electrical Impedance Spectroscopy (EIS) to deliver precise, objective information. This invaluable data supports dermatologists and healthcare professionals in making confident clinical decisions that can change lives.
Our game-changing product lineup includes Nevisense and Nevisense Go, targeting critical areas like melanoma detection, non-melanoma skin cancer identification, and skin barrier assessment. Notably, Nevisense holds the prestigious distinction of being the sole FDA-approved device for melanoma detection, as well as the only MDR-approved technology for skin cancer detection in Europe.
Our roots run deep, with over two decades of academic research at the world-renowned Karolinska Institute in Stockholm, Sweden, forming the bedrock of our groundbreaking technology. Join us on this extraordinary journey as we continue to redefine the future of skin health.